This strategy has been identified in the extension of the time interval between NTZ infusions leaving opened several questions regarding the optimal interval time and the duration of strategy assuring the maintenance of clinical efficacy. Recently, using data from Tysabri Outreach: Unified Commitment to...
(e.g., metronidazole) AND There is documentation in the medical record that the patient had an inadequate response, intolerance, or contraindication to ONE of the following medications: Humira (adalimumab), Cimzia (certilizumab pegol), Remicade (infliximab), Entyvio (vedolizumab), ...